ARCHIVES

Drug Shortage A Boon For Levoleucovorin; Price Is 60 Times Higher Than Leucovorin

This article is from The Cancer Letter archive.

Vol. 35 No. 02 | January 16, 2009

Download PDF Visit The Full Archive

Related Articles

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001

Wallen Pleads Guilty To Lesser Charges, To Pay $20,000 to CALGB, FDA

August 31, 1984

In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb

July 14, 1995

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

Kennedy Bill Would Extend Cancer Program Three Years, Kill Budget Bypass

May 4, 1979

Clinical Trials Approved By NCI Last Month

March 29, 2002